TMAO – en förening som bildas när tarmbakterier bryter ned näringsämnen från rött kött, ägg och fisk (kolin, L-karnitin, fosfatidylkolin) – har nu direkt kopplats till ärrbildning (fibros) i njurar, hjärta och lever. Processen inleds helt och hållet i tarmen: tarmmikrober omvandlar näringsämnen från kosten → TMA → levern omvandlar det → TMAO i blodet. Kroniskt förhöjda TMAO-nivåer är inte bara ett tecken på sjukdom — de orsakar aktivt organskador genom flera molekylära mekanismer.
Tissue fibrosis — the excessive buildup of scar tissue (extracellular matrix) in organs — is responsible for up to 45% of all deaths in industrialized nations. It’s the final common pathway in diseases like chronic kidney disease, heart failure, fatty liver disease, and systemic sclerosis. Despite its prevalence, the root causes are poorly understood.
This review paper reveals that the gut microbiome plays a central and previously underappreciated role in driving fibrosis. Gut bacteria metabolize dietary precursors into TMA, which the liver enzyme FMO3 converts into TMAO. Chronically elevated TMAO then activates pro-fibrotic signaling cascades — TGF-β/SMAD3, NLRP3 inflammasome, PERK/Akt/mTOR — across multiple organ systems simultaneously.
Crucially, the paper also reviews therapeutic strategies: dietary changes, probiotics, and especially small-molecule TMA lyase inhibitors (DMB and IMC) that can reduce TMAO without killing gut bacteria — a gentler, more targeted approach than antibiotics.
Kidney
Heart
Liver
Systemic Sclerosis
Therapeutic Strategies
Jang JW, Capaldi E, Smith T, Verma P, Varga J, Ho KJ. Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis. Molecular Medicine. 2024;30:128.